Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets in 2026. It reportedly works as well as Ozempic.

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

The Big Money Show' panel discusses President Donald Trump's plan to bring drug manufacturing back to the U.S.

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning.